Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIFICOPEC
- Development stage
- Phase 2
- Lead developer
- Jinling Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BIFICOPEC is a synbiotic therapy developed by Jinling Hospital in China for the treatment of slow transit constipation (STC). It consists of a combination of a triple-viable probiotic preparation (marketed as BIFICO, containing *Enterococcus*, *Bifidobacterium*, and *Lactobacillus*) and pectin, a soluble dietary fiber that functions as a prebiotic. The therapy is designed to modulate the gut microbiota and enhance gastrointestinal motility. Clinical evidence from a Phase 2 randomized, placebo-controlled trial (NCT02844426) indicates that 12 weeks of BIFICOPEC supplementation significantly increases bowel movement frequency, improves symptom scores, and decreases colonic transit time in adult patients with STC.
- Brand names
- BIFICOPEC
- Other names
- bifid triple viable capsule and pectinsynbiotic (BIFICOPEC)BIFICO plus pectin
Beyond the preview
Go deeper on BIFICOPEC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIFICOPEC.